Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07911514). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Healthy Participants. Interventions: DRUG: AZD9550 solution for injection; DRUG: AZD6234 solution for injection; DRUG: Formulation 1 solution for injection; DRUG: Formulation 2 solution for injection; DRUG: Formulation 3 solution for injection; DRUG: Formulation 4 solution for injection. Primary outcome measures: Maximum observed plasma concentration (Cmax) , Plasma sample collection from pre dose to Day 22; Area under the curve from time 0 to the time of last quantifiable concentration (AUClast) , Plasma sample collection from pre dose to Day 22; Area under the curve from time 0 extrapolated to infinity (AUCinf) , Plasma sample collection from pre dose to Day 22. Brief summary: This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.